These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 15962284)

  • 1. A viral kinetic study using pegylated interferon alfa-2b and/or lamivudine in patients with chronic hepatitis B/HBeAg negative.
    Sypsa VA; Mimidis K; Tassopoulos NC; Chrysagis D; Vassiliadis T; Moulakakis A; Raptopoulou M; Haida C; Hatzakis A
    Hepatology; 2005 Jul; 42(1):77-85. PubMed ID: 15962284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peginterferon alfa-2b as monotherapy or in combination with lamivudine in patients with HBeAg-negative chronic hepatitis B: a randomised study.
    Papadopoulos VP; Chrysagis DN; Protopapas AN; Goulis IG; Dimitriadis GT; Mimidis KP
    Med Sci Monit; 2009 Feb; 15(2):CR56-61. PubMed ID: 19179968
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.
    Lau GK; Piratvisuth T; Luo KX; Marcellin P; Thongsawat S; Cooksley G; Gane E; Fried MW; Chow WC; Paik SW; Chang WY; Berg T; Flisiak R; McCloud P; Pluck N;
    N Engl J Med; 2005 Jun; 352(26):2682-95. PubMed ID: 15987917
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modelling of early viral kinetics and pegylated interferon-alpha2b pharmacokinetics in patients with HBeag-positive chronic hepatitis B.
    ter Borg MJ; Hansen BE; Herrmann E; Zeuzem S; Cakaloglu Y; Karayalcin S; Flisiak R; van' t Veen A; de Man RA; Schalm SW; Janssen HL; Haagmans BL;
    Antivir Ther; 2007; 12(8):1285-94. PubMed ID: 18240868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peg-interferon improves liver histology in patients with HBeAg-positive chronic hepatitis B: no additional benefit of combination with lamivudine.
    van Zonneveld M; Zondervan PE; Cakaloglu Y; Simon C; Akarca US; So TM; Flink HJ; de Man RA; Schalm SW; Janssen HL;
    Liver Int; 2006 May; 26(4):399-405. PubMed ID: 16629642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multiphase model of the dynamics of HBV infection in HBeAg-negative patients during pegylated interferon-alpha2a, lamivudine and combination therapy.
    Colombatto P; Civitano L; Bizzarri R; Oliveri F; Choudhury S; Gieschke R; Bonino F; Brunetto MR;
    Antivir Ther; 2006; 11(2):197-212. PubMed ID: 16640101
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early HBeAg loss during peginterferon alpha-2b therapy predicts HBsAg loss: results of a long-term follow-up study in chronic hepatitis B patients.
    Buster EH; Flink HJ; Simsek H; Heathcote EJ; Sharmila S; Kitis GE; Gerken G; Buti M; de Vries RA; Verhey E; Hansen BE; Janssen HL
    Am J Gastroenterol; 2009 Oct; 104(10):2449-57. PubMed ID: 19584831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial.
    Janssen HL; van Zonneveld M; Senturk H; Zeuzem S; Akarca US; Cakaloglu Y; Simon C; So TM; Gerken G; de Man RA; Niesters HG; Zondervan P; Hansen B; Schalm SW; ;
    Lancet; 2005 Jan 8-14; 365(9454):123-9. PubMed ID: 15639293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lamivudine/pegylated interferon alfa-2b sequential combination therapy compared with lamivudine monotherapy in HBeAg-negative chronic hepatitis B.
    Vassiliadis T; Tziomalos K; Patsiaoura K; Zagris T; Giouleme O; Soufleris K; Grammatikos N; Theodoropoulos K; Mpoumponaris A; Dona K; Zezos P; Nikolaidis N; Orfanou-Koumerkeridou E; Balaska A; Eugenidis N
    J Gastroenterol Hepatol; 2007 Oct; 22(10):1582-8. PubMed ID: 17683500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patterns of viral decline during PEG-interferon alpha-2b therapy in HBeAg-positive chronic hepatitis B: relation to treatment response.
    ter Borg MJ; van Zonneveld M; Zeuzem S; Senturk H; Akarca US; Simon C; Hansen BE; Haagmans BL; de Man RA; Schalm SW; Janssen HL;
    Hepatology; 2006 Sep; 44(3):721-7. PubMed ID: 16941701
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.
    Marcellin P; Lau GK; Bonino F; Farci P; Hadziyannis S; Jin R; Lu ZM; Piratvisuth T; Germanidis G; Yurdaydin C; Diago M; Gurel S; Lai MY; Button P; Pluck N;
    N Engl J Med; 2004 Sep; 351(12):1206-17. PubMed ID: 15371578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized, open-label clinical study of combined pegylated interferon Alfa-2a (40KD) and entecavir treatment for hepatitis B "e" antigen-positive chronic hepatitis B.
    Xie Q; Zhou H; Bai X; Wu S; Chen JJ; Sheng J; Xie Y; Chen C; Chan HL; Zhao M
    Clin Infect Dis; 2014 Dec; 59(12):1714-23. PubMed ID: 25190434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful treatment with peginterferon alfa-2b of HBeAg-positive HBV non-responders to standard interferon or lamivudine.
    Flink HJ; Hansen BE; Heathcote EJ; Feinman SV; Simsek H; Karayalcin S; Mach T; Leemans WF; de Man RA; Verhey E; Schalm SW; Janssen HL;
    Am J Gastroenterol; 2006 Nov; 101(11):2523-9. PubMed ID: 17029610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pegylated interferon Alfa-2b monotherapy and pegylated interferon Alfa-2b plus lamivudine combination therapy for patients with hepatitis B virus E antigen-negative chronic hepatitis B.
    Kaymakoglu S; Oguz D; Gur G; Gurel S; Tankurt E; Ersöz G; Ozenirler S; Kalayci C; Poturoglu S; Cakaloglu Y; Okten A
    Antimicrob Agents Chemother; 2007 Aug; 51(8):3020-2. PubMed ID: 17517832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pretreatment with pegylated interferon prevents emergence of lamivudine mutants in lamivudine-naive patients: a pilot study.
    Villa E; Lei B; Taliani G; Graziosi A; Critelli R; Luongo M; Gennari W; Bianchini M; Ferretti I
    Antivir Ther; 2009; 14(8):1081-7. PubMed ID: 20032538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment with Peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype.
    Flink HJ; van Zonneveld M; Hansen BE; de Man RA; Schalm SW; Janssen HL;
    Am J Gastroenterol; 2006 Feb; 101(2):297-303. PubMed ID: 16454834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interferon and lamivudine combination therapy versus lamivudine monotherapy for hepatitis B e antigen-negative hepatitis B treatment: a meta-analysis of randomized controlled trials.
    Shi Y; Wu YH; Shu ZY; Zhang WJ; Yang J; Chen Z
    Hepatobiliary Pancreat Dis Int; 2010 Oct; 9(5):462-72. PubMed ID: 20943454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of pegylated interferon-alpha on the treatment of lamivudine resistant chronic HBeAg positive hepatitis B virus infection.
    Leemans WF; Flink HJ; Janssen HL; Niesters HG; Schalm SW; de Man RA
    J Hepatol; 2006 Mar; 44(3):507-11. PubMed ID: 16457904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of pegylated interferon and lamivudine for patients with chronic hepatitis B who have failed treatment.
    Sarin SK; Kumar M; Hissar S; Sharma BC
    Hepatobiliary Pancreat Dis Int; 2006 Aug; 5(3):374-80. PubMed ID: 16911934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Experiences in antiviral treatment of chronic viral hepatitis B and C in Hungary (1998-2004)].
    Pár A; Tornai I; Szalay F
    Orv Hetil; 2007 May; 148(18):819-26. PubMed ID: 17468063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.